{"id":"baminercept-alfa-4","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Muscle pain"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1742988","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism of action is based on the principle of blocking the pro-inflammatory effects of TNF, a cytokine involved in systemic inflammation and one of the cytokines that make up the acute phase reaction, which is part of the initial immune response.","oneSentence":"Baminercept alfa 4 is a fusion protein that targets and binds to the soluble form of tumor necrosis factor (TNF) to prevent its interaction with cell surface TNF receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:10.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT00664573","phase":"PHASE2","title":"104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2007-11","conditions":"Rheumatoid Arthritis","enrollment":339},{"nctId":"NCT00664716","phase":"PHASE2","title":"Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-07","conditions":"Rheumatoid Arthritis","enrollment":391}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BG9924","LT beta"],"phase":"phase_2","status":"active","brandName":"Baminercept alfa 4","genericName":"Baminercept alfa 4","companyName":"Biogen","companyId":"biogen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Baminercept alfa 4 is a fusion protein that targets and binds to the soluble form of tumor necrosis factor (TNF) to prevent its interaction with cell surface TNF receptors. Used for Moderate to severe plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}